Shares of Immunomedics Inc. (NASDAQ:IMMU) traded up 2.8% on Thursday . The company traded as high as $2.60 and last traded at $2.59, with a volume of 1,642,196 shares traded. The stock had previously closed at $2.52.

A number of analysts recently weighed in on the stock. Wells Fargo & Co. reissued a “buy” rating on shares of Immunomedics in a research report on Tuesday, May 24th. Jefferies Group reissued a “buy” rating and issued a $5.00 price objective on shares of Immunomedics in a research report on Monday, June 6th. Finally, Zacks Investment Research lowered shares of Immunomedics from a “buy” rating to a “sell” rating in a research report on Tuesday, May 10th.

The company’s market cap is $245.54 million. The company has a 50-day moving average price of $2.73 and a 200 day moving average price of $2.76.

Immunomedics (NASDAQ:IMMU) last announced its earnings results on Wednesday, May 4th. The biopharmaceutical company reported ($0.15) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.13) by $0.02. Analysts anticipate that Immunomedics Inc. will post ($0.57) earnings per share for the current fiscal year.

In other news, CEO Cynthia L. Goldenberg sold 41,441 shares of Immunomedics stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $3.62, for a total value of $150,016.42. Following the sale, the chief executive officer now owns 703,029 shares in the company, valued at $2,544,964.98. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Chairman David M. Goldenberg sold 353,010 shares of Immunomedics stock in a transaction dated Wednesday, June 8th. The shares were sold at an average price of $3.88, for a total transaction of $1,369,678.80. Following the completion of the sale, the chairman now owns 2,602,063 shares in the company, valued at approximately $10,096,004.44. The disclosure for this sale can be found here.

An institutional investor recently bought a new position in Immunomedics stock. Marshall Wace LLP bought a new stake in shares of Immunomedics Inc. (NASDAQ:IMMU) during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm bought 857,062 shares of the biopharmaceutical company’s stock, valued at approximately $2,631,000. Marshall Wace LLP owned 0.90% of Immunomedics at the end of the most recent quarter.

Immunomedics, Inc is a clinical-stage biopharmaceutical company developing monoclonal antibody-based products for the targeted treatment of cancer, autoimmune disorders and other serious diseases. The Company’s technologies allow it to create humanized antibodies in unlabeled or naked form, or conjugated with radioactive isotopes, chemotherapeutics, cytokines or toxins.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.